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Purpose: To investigate the effect of cysteamine (CYS) on mixed peripheral blood mononuclear cells (PBMCs) - human
corneal endothelial cell (HCEC) reaction (MLER).
Methods:  PBMC  stimulation  assay  was  performed  using  cultured  HCEC.  MLERs  were  treated  with  various
concentrations of CYS (0–20 mM). The proliferation rate and secretion profiles of transforming growth factor-β1 (TGF-
β1)  and  interleukin-6  (IL-6)  of  PBMCs  stimulated  by  cultured  HCEC  were  determined  using  bromodeoxyuridine
proliferation assay and enzyme-linked immunosorbent assay, respectively.
Results: CYS suppressed PBMC proliferation in a dose-dependent manner (p<0.001). The intracellular reactive oxygen
species (ROS) levels decreased with an increase in CYS concentration (p<0.001). The levels of TGF-β1 and IL-6 decreased
in a dose-dependent manner as well (p=0.011 and 0.003, respectively).
Conclusions: This study showed that CYS decreased PBMC proliferation, IL-6 and TGF-β1 levels via ROS formation.
Our results suggest that CYS could suppress inflammation associated with PBMCs to corneal endothelial cells.
Allograft corneal transplantation is widely performed to
treat corneal diseases, including bullous keratopathy, Fuchs’
endothelial dystrophy, and corneal opacity [1]. Rejection is a
major  complication  after  allograft  corneal  transplantation
[1-3]. The cornea has been described as an immune-privileged
site because cornea has no blood or lymphatic vessels [4].
Allograft  rejection  after  penetrating  keratoplasty  or
endothelial  transplantation.  However,  corneal  endothelial
rejection can cause persistent graft edema and failure [1,5]
while epithelial rejection is usually self limited. Suppression
of  corneal  endothelial  rejection  is  important  to  maintain
endothelial function and transparency of grafts [6]. Many
drugs  have  been  developed  to  suppress  the  inflammation
associated  with  organ  transplantation  including  corneal
endothelial  rejection  after  corneal  transplant  [7-9].  The
mainstay is the use of immunosuppressive agents including
rapamycin, steroid, and cyclosporine A [10].
Recently,  reactive  oxygen  species  (ROS)  has  been
described to induce the inflammation [11,12]. It has been
reported that antioxidants play an essential role in inhibiting
inflammation [13,14]. However, there has been no study about
the role of antioxidants in corneal endothelial rejection after
corneal  transplantation.  Cysteamine  (CYS)  is  a  simple
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aminothiol that participates in various physiologic processes,
including amino acid transport, disulfide reduction, protein
synthesis, and protection against oxidative damage [15-18].
CYS  has  been  described  as  an  anti-oxidant  [19].  CYS
enhances glutathione (GSH) synthesis under various forms of
toxic stress [18]; furthermore, it exerts a potent and prolonged
anti-inflammatory  effect  [20,21].  In  this  study,  we
investigated  the  effects  of  CYS  on  corneal  endothelilal
rejection  via  the  interactions  between  peripheral  blood
mononuclear cells (PBMCs) and human corneal endothelial
cells (HCECs).
METHODS
This  study  was  performed  according  to  the  tenets  of  the
Declaration of Helsinki, and was reviewed and approved by
the institutional review board/ethics committee of Hallym
University  Medical  Center.  HCECs  were  obtained  from
discarded corneal-scleral rings after penetrating keratoplasty.
These tissues were stored in Optisol™-GS (Bausch and Lomb
Inc., Rochester, NY) at 4 °C until processed for culture.
Human corneal endothelial cell culture: HCECs were
cultured in accordance with previously published methods
[22]. HCECs from the remnant donor tissues after corneal
transplantation were harvested on or before the 7th day after
death.  All  of  the  cells  remained  attached  to  Descemet’s
membrane. The endothelial cells and Descemet’s membrane
complex were incubated for 1 h in 0.02% EDTA solution,
stirred vigorously with a flame-polished pipette to disrupt cell
junctions, centrifuged for 5 min at 3000× g, and seeded onto
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3371culture plates coated with FNC coating mix (Athena Enzyme
System,  Baltimore,  MD)  containing  bovine  fibronectin
(10 μg/ml) and bovine type I collagen (35 μg/ml). The cells
were then cultured in OptiMem-I media (GIBCO/BRL Life
technologies, Grand Island, NY) supplemented with 8% FBS
(Cambrex  Bio  Science,  Walkersville,  MD),  200  mg/l  of
calcium chloride (Sigma Chemical Co. St. Louis, MO), 0.08%
chondroitin sulfate (Sigma Chemical Co.), 20 μg/ml ascorbic
acid  (Sigma  Chemical  Co.),  100  μg/ml  pituitary  extract
(Invitrogen, Grand Island, NY), 5 ng/ml epidermal growth
factor (Sigma Chemical Co.), 20 ng/ml nerve growth factor
(Sigma Chemical Co.), 10 μg/ml gentamicin (Invitrogen),
100 IU/ml penicillin (Cambrex Bio Science, Walkersville,
MD), 100 IU/ml streptomycin (Cambrex Bio Science), and
2.5  μg/ml  amphotericin  (Cambrex  Bio  Science)  under  an
atmosphere of 5% CO2. The medium was changed every 2
days. At confluence, the cells were split 1 to 3, and cells from
passage 4 were used for experiments.
Immunofluorescence staining: HCECs cultured on cover
glasses  in  12-well  plates  were  washed  with  phosphate
buffered  saline  (PBS)  and  fixed  for  20  min  in  3.7%
formaldehyde solution. The cells were permeabilized for 10
min with 0.5% Triton X-100 and blocked for 1 h with 1% BSA
at room temperature. After washing, the cells were incubated
overnight  with  rabbit  polyclonal  antibody  to  zonular
occludence-1  (ZO-1;  Zymed  Laboratories,  San  Francisco,
CA) at 4 °C, then washed with PBS. The cells were incubated
with  FITC-conjugated  donkey  anti-rabbit  IgG  antibody
(1:100) for 1 h at 37 °C in the dark, then counterstained with
Hoechst  nuclear  staining  dye  (1:2,000;  Molecular  Probes,
Leiden,  The  Netherlands)  in  accordance  with  the
manufacturer’s recommendations. After extensive washing
with PBS, the slides were mounted in a drop of mounting
medium to reduce photobleaching. Negative control staining
was  conducted  in  parallel  with  the  omission  of  primary
antibodies.
PBMC isolation: Heparinized fresh whole blood (10 IU
heparin/ml) was diluted 1:2 with PBS solution. The peripheral
blood mononuclear cell (PBMC) fraction was obtained by
Ficoll-Hypaque centrifugation. The cells were then washed in
PBS before culture. The PBMCs were cultured for 24 h at
37  °C  at  a  density  of  1×106  cells/well  in  Roswell  Park
Memorial Institute (RPMI) medium supplemented with 5%
(vol/vol)  fetal  calf  serum.  The  viability  of  PBMCs  was
measured by trypan blue dye exclusion and was consistently
greater  than  98%.  The  cells  were  then  suspended  in
RPMI-1640 (Invitrogen-Life Technologies).
Mixed  PBMC–HCEC  reaction  (MLER):  PBMC
stimulation  assay  was  performed  to  determine
immunoreactivity, as previously described [23,24]. In this
study, mitomycin C-treated HCECs (5×105/ml) were used as
stimulating cells. These cells were incubated with 25 µg/ml
mitomycin C for 30 min in a 5% CO2 humidified incubator.
Residual mitomycin C was removed by repeated washing (3
times) with RPMI 1640 containing 10% fetal bovine serum.
Then, the stimulating and responding cells were cocultured in
100 μl of RPMI 1640 in 96-well plates and incubated for 2
days either with 0–20 mM CYS. After incubation, PBMC
proliferation  was  measured  using  a  commercial
bromodeoxyuridine  (BrdU)  proliferation  assay  kit  (Roche
Diagnostics GmbH., Mannheim, Germany) according to the
manufacturer’s protocol. One hundred microliters of PBMC
cell suspension (1×106 cells/well) was added to 5 wells of flat-
bottomed 96-well plates. Unstimulated PBMCs served as the
negative  control,  whereas  PBMCs  treated  with
phytohemagglutinin (PHA, 5 µg/ml; Sigma Chemical Co.)
served as the positive control. Optical density was measured
at  450  nm  with  an  enzyme-linked  immunosorbent  assay
(ELISA) reader. The results are expressed as mean (standard
deviation [SD]). Three times of experiments were repeated.
Proliferation rates were calculated as the percentage increase
in  the  number  of  cells  between  PHA-stimulated  and
unstimulated  cultures  after  subtracting  the  corresponding
blanks.  Proliferation  rates  were  calculated  as  follows:
percentage of BrdU proliferation (%)=(mean optical density
(O.D.) in sample – mean O.D. in unstimulated cultures) /
(mean  O.D.  in  PHA-stimulated  cultures  -  mean  O.D.  in
unstimulated cultures) × 100.
Enzyme-linked  immunosorbent  assay  (ELISA):  The
supernatant was collected after centrifugation at 300× g for 10
min, and frozen at −70 °C until used to determine the cytokine
levels. The levels of interleukin-6 (IL-6) and transforming
growth factor-β (TGF-β) in the PBMC culture medium were
assayed using commercial human IL-6 and TGF-β ELISA kits
(R&D  Systems,  Minneapolis,  MN)  according  to  the
manufacturer’s protocols. The sensitivity limit of each ELISA
was ~15 pg/ml. In brief, anti-human TGF-β1 or IL-6 antibody
was added to each well of a 96-well microtiter plate and
incubated overnight at room temperature (RT). The next day,
each  well  was  washed  with  washing  buffer,  filled  with  a
blocking  buffer  (pH  7.4)  containing  1%  BSA,  and  then
incubated at RT for 1 h. One hundred-microliter standard
dilutions  of  human  TGF-β1  or  IL-6  (obtained  from  the
experimental samples) were dispensed into the wells of a 96-
well  microtiter  plate;  these  wells  were  coated  with  an
appropriate polyclonal antibody. The plate was sealed and
incubated at RT for 2 h. After incubation, the plates were
washed 4 times, and 100 μl of goat anti-human TGF-β1 or
IL-6  antibody  conjugated  to  horseradish  peroxidase  was
added to each well, and the plates were incubated at RT for 2
h. One hundred-microliter aliquots of a color reagent (3,3′,
5,5′-tetramethylbenzidine [TMB]) were then applied to the
plates for 20 min to obtain a blue color; the reaction was
stopped by adding 50 μl of 1 M H2SO4. The absorbance was
measured at 450 nm by using an automatic plate reader with
a 570 nm reference wavelength.
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3372Figure 1. Human corneal endothelial cell examination. Inverted phase-contrast imaging (A) and immunofluorescent ZO-1 staining (B) of the
human corneal endothelial cells. Human corneal endothelial cells were observed in mosaic pattern. Immunofluorescence with anti-ZO-1
antibody, a general marker of the tight junction, revealed the morphology. The nuclei were stained using Hoechst 33342 (blue). Magnification,
200×.
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3373Measurement  of  intracellular  reactive  oxygen  species
formation: Reactive oxygen species (ROS) formation was
measured  using  the  oxidation-sensitive  fluorescent  probe,
2′7′-dichlorofluorescein  diacetate  (DCFH-DA;  D6665;
Sigma Chemical Co.); this measurement is based on the ROS-
dependent oxidation of DCFH-DA to 2′7′-dichlorofluorescein
(DCF). MLERs were incubated with 0–20 mM CYS for 48 h,
suspension cells were collected, and were then centrifuged at
300× g for 10 min. The supernatant was discarded, and the
cells were washed with PBS. Then, the cell suspension was
centrifuged at 300× g for 10 min. Subsequently, 200 µl of
10 μM DCFH-DA was added, and the cells were incubated
for further 30 min at 37 °C in darkness. These cells were then
washed  with  PBS.  Intracellular  ROS  production  was
measured  using  the  previously  described  DCFH-DA
microplate assay method [22]. We used a spectrofluorometer
(SFM  25;  Kontron  Instruments,  Basel,  Switzerland)  to
measure ROS generation by the fluorescence intensity in each
well at an excitation wavelength of 495 nm and an emissions
wavelength  of  530  nm.  Relative  intensities  of  DCF
fluorescence  were  calculated  by  setting  the  fluorescence
intensity  of  the  PHA-stimulated  cultures  to  100%  after
subtracting the corresponding blanks.
RESULTS
HCECs culture: The cultured HCECs showed growth (Figure
1A). Immunofluorescence with ZO-1, a marker of the tight
junction, revealed the morphology (Figure 1B). The nuclei
were stained with Hoechst Mann–Whitney U test).
Intracellular ROS measurement: CYS decreased intracellular
ROS levels in a dose-dependent manner (p<0.001; Kruskal–
Wallis test; Figure 2). The DCF assay showed that a CYS
concentration  of  ≥0.5  mM  reduced  the  intracellular  ROS
levels (p=0.006, 0.006, 0.004, and 0.004, respectively; Mann–
Whitney U test).
IL-6 secretion profiles of activated PBMCs: CYS decreased
IL-6 levels in a dose-dependent manner (p=0.003; Kruskal–
Wallis  test;  Figure  3).  CYS  concentration  of  ≥1  mM
significantly lowered the IL-6 levels (p=0.034, 0.021, and
0.021, respectively; Mann–Whitney U test).
TGF-β1 secretion profiles of activated PBMCs: The TGF-β1
levels  decreased  with  an  increase  in  CYS  concentration
(p=0.011;  Kruskal–Wallis  test;  Figure  4).  A  CYS
concentration of ≥1 mM significantly lowered the TGF-β1
levels  (p=0.034,  0.034,  and  0.021,  respectively;  Mann–
Whitney U test).33342.
PBMC stimulation assay: Mitomycin C-treated HCECs were
used  as  stimulating  cells.  CYS  suppressed  PBMC
proliferation in a dose-dependent manner (p<0.001; Kruskal–
Wallis test; Figure 5). PBMC proliferation was suppressed
with ≥1 mM of CYS (p=0.016, 0.009, and 0.009, respectively;
DISCUSSION
Endothelial  rejection  involves  inflammatory  signals,
including keratic precipitates and inflammation in the anterior
chamber [1,5]. Leukocyte counts in the graft bed are inversely
correlated  with  actuarial  graft  survival  [25].  Corneal
endothelial rejection has been known as the most severe form
of rejections [26,27]. Two forms of endothelial rejection have
been described [27]. Khodadoust line in endothelial rejection
usually originates at a vascularized area of the cornea [27], or
at the site of an anterior synechiae [26]. Within a few days,
Figure  2.  Relative  2′
′dichlorofluorescein  (DCF)
fluorescence.  CYS  decreased
intracellular  ROS  levels  in  a  dose-
dependent manner (p<0.001; Kruskal–
Wallis  test).  PHA-stimulated  PBMCs
served  as  the  positive  control  and
unstimulated  PBMCs  served  as  the
negative  control.  *:  statistically
significant  by  the  Mann–Whitney  U
test.
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3374the  line  extends  across  the  donor  cornea,  destroying
endothelial cells, depositing keratic precipitates. The other
form  is  diffuse  endotheliitis  although  diffuse  keratic
precipitates are not visible. Endothelial rejection is one of
inflammatory  responses.  Endothelial  rejection  is  one  of
inflammatory responses although the corneal endothelial cell
rejection has been known to be mediated by a chronic adaptive
immunity  [28]  and  it  is  not  well  established  that  simply
inflammation plays a major role in this process. Thus, the
interaction between PBMC and HCEC is important for graft
survival.
In this study, we showed that CYS suppresses PBMC
proliferation and decreases intracellular ROS levels in a dose-
dependent  manner.  CYS  is  an  antioxidant  that  enhances
intracellular  GSH  levels.  Moreover,  CYS  may  act  as  a
scavenger of superoxide free radicals and hydrogen peroxide
[29]. ROS have been described to modulate inflammation and
tissue repair [30]. Although ROS causes cell death at high
level [22], a low level of ROS has been described to mediate
cell signaling events in inflammation as a second messenger
[30].  Reduction  of  intracellular  ROS  can  reduce  the  cell
proliferation  and  inflammatory  response.  Nuclear  factor-
Figure 4.  TGF-β  levels  measured  by
enzyme-linked  immunosorbent  assay
(ELISA). CYS decreased TGF-β levels
in a dose-dependent manner (p=0.011;
Kruskal–Wallis  test).  PHA-stimulated
PBMCs served as the positive control
and unstimulated PBMCs served as the
negative  control.  *:  statistically
significant  by  the  Mann–Whitney  U
test.
Figure 3.  IL-6  levels  measured  by
ELISA. The IL-6 levels decreased with
an increase in the CYS concentration
(p=0.003; Kruskal–Wallis test). PHA-
stimulated  PBMCs  served  as  the
positive  control  and  unstimulated
PBMCs served as the negative control.
*: statistically significant by the Mann–
Whitney U test.
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3375erythroid  2-related  factor  2  (Nrf2),  a  redox-sensitive
transcription factor, has been implicated in cellular responses
to oxidative stress; Nrf2 inhibits nuclear factor kappa B (Nf-
κB) [31,32], which plays a key role in immune response and
inflammation  [33].  Thus,  CYS  may  exert  an  anti-
inflammatory effect by reducing intracellular ROS formation.
In addition, CYS suppressed the levels of IL-6 and TGF-β1,
which are the cytokines secreted by PBMCs [34,35]. Nf-κB
has  been  reported  to  induce  the  activation  of  IL-6  gene
expression [36,37] and to be regulated by TGF-β1 [38,39].
IL-6 is a proinflammatory cytokine that plays multiple roles
during  injuries  and  inflammation  [32].  IL-6  levels  in  the
human  aqueous  humor  have  been  reported  to  rise  during
corneal endothelial immune reactions [40,41]. It has been
reported  that  the  specific  release  of  proinflammatory
cytokines  from  alloreactive  infiltrating  cells,  results  in
apoptosis  in  the  corneal  endothelium  [42].  TGF-β1  is  a
multifunctional cytokine [43]. Although the role of TGF-β1
in corneal endothelial rejection is yet unclear, TGF-β1 has
been reported to be induced by tissue injuries, participate in
tissue fibrosis [40], and regulate inflammation and fibrosis
[44]. TGF-β1 has been reported to modulate Nf-κB [38,39],
which plays a key role in inflammatory response [33]. Thus,
TGF-β1 might regulate the immune response during corneal
endothelial rejection.
In our previous study, we showed that, while 10 mM of
CYS is not toxic to cultured corneal endothelial cells, higher
concentrations of CYS are lethal [45]. We also reported that
CYS protects HCECs against oxidative injury-mediated cell
death by inhibiting ROS production at high concentrations of
CYS [45]. Therefore, low concentrations of CYS could not
only effectively suppress inflammation but also be nontoxic
to corneal endothelial cells.
In conclusion, this study showed that CYS decreased
PBMC  proliferation,  IL-6  and  TGF-β1  levels  via  ROS
formation.  Our  results  suggest  that  CYS  could  suppress
inflammation associated with PBMCs to corneal endothelial
cells. However, further in vivo studies are required.
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